Esperion Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Halladay Benjamin unloaded Company’s shares for reported $5242.0 on Mar 18 ’25. In the deal valued at $1.48 per share,3,535 shares were sold. As a result of this transaction, Halladay Benjamin now holds 481,710 shares worth roughly $0.48 million.
Then, Warren Eric sold 2,433 shares, generating $3,618 in total proceeds. Upon selling the shares at $1.49, the Chief Commercial Officer now owns 370,326 shares.
Before that, Koenig Sheldon L. sold 13,047 shares. Esperion Therapeutics Inc shares valued at $19,623 were divested by the President and CEO at a price of $1.50 per share. As a result of the transaction, Koenig Sheldon L. now holds 1,571,962 shares, worth roughly $1.57 million.
Goldman initiated its Esperion Therapeutics Inc [ESPR] rating to a Neutral in a research note published on December 18, 2024; the price target was $4. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid December with a ‘”an Overweight”‘ rating. BofA Securities also remained covering ESPR and has decreased its forecast on June 20, 2024 with a “an Underperform” recommendation from previously “Neutral” rating. BofA Securities revised its rating on January 03, 2024. It rated ESPR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ESPR
On Monday, Esperion Therapeutics Inc [NASDAQ:ESPR] saw its stock fall -2.05% to $1.00. Over the last five days, the stock has lost -16.74%. Esperion Therapeutics Inc shares have fallen nearly -54.59% since the year began. Nevertheless, the stocks have fallen -56.75% over the past one year. While a 52-week high of $3.94 was reached on 01/14/25, a 52-week low of $0.93 was recorded on 04/10/25. SMA at 50 days reached $1.5958, while 200 days put it at $2.0262.
Levels Of Support And Resistance For ESPR Stock
The 24-hour chart illustrates a support level at 0.9701, which if violated will result in even more drops to 0.9410. On the upside, there is a resistance level at 1.0391. A further resistance level may holdings at 1.0790. The Relative Strength Index (RSI) on the 14-day chart is 24.37, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.2776, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.44%. Stochastics %K at 8.53% indicates the stock is a buying.
How much short interest is there in Esperion Therapeutics Inc?
A steep rise in short interest was recorded in Esperion Therapeutics Inc stocks on 2025-03-31, dropping by -1.12 million shares to a total of 28.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 29.14 million shares. There was a decline of -4.0%, which implies that there is a negative sentiment for the stock.
